Trial Profile
Anlotinib plus 125I seed versus 125I seed alone for the treatment of progress or intolerance advanced non-small-cell lung cancer after system chemotherapy
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 20 Sep 2018
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 20 Sep 2018 New trial record